Almut Mecke

989 total citations
10 papers, 150 citations indexed

About

Almut Mecke is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Almut Mecke has authored 10 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Surgery and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Almut Mecke's work include Cancer Immunotherapy and Biomarkers (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Urinary and Genital Oncology Studies (3 papers). Almut Mecke is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Urinary and Genital Oncology Studies (3 papers). Almut Mecke collaborates with scholars based in Switzerland, United States and Spain. Almut Mecke's co-authors include Sandhya Girish, René Bruno, Jin Y. Jin, Mathilde Marchand, Helen Winter, Hina Patel, Kari M. Morrissey, Rong Zhang, Benjamin Wu and Ian D. Davis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Almut Mecke

9 papers receiving 149 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Almut Mecke Switzerland	6	105	62	40	35	18	10	150
Alessandro Pastorino Italy	7	129 1.2×	45 0.7×	32 0.8×	10 0.3×	7 0.4×	26	172
Igor Lifirenko Russia	4	118 1.1×	34 0.5×	83 2.1×	22 0.6×	22 1.2×	4	182
N. Zanaletti Italy	8	133 1.3×	45 0.7×	35 0.9×	26 0.7×	14 0.8×	20	156
Yabing Guo China	8	87 0.8×	43 0.7×	27 0.7×	33 0.9×	6 0.3×	15	270
Н. В. Коваленко Russia	8	84 0.8×	25 0.4×	25 0.6×	46 1.3×	38 2.1×	25	167
Hendrik Kroening Germany	9	271 2.6×	48 0.8×	107 2.7×	63 1.8×	7 0.4×	21	321
Louis Marie Dourthe France	2	92 0.9×	60 1.0×	104 2.6×	14 0.4×	31 1.7×	5	180
Jennifer Friedmann Canada	6	108 1.0×	21 0.3×	58 1.4×	40 1.1×	9 0.5×	16	157
Natalie Q. Wang Canada	2	53 0.5×	79 1.3×	111 2.8×	15 0.4×	13 0.7×	2	172
Cédrik Lafond France	8	181 1.7×	78 1.3×	109 2.7×	36 1.0×	8 0.4×	12	260

Countries citing papers authored by Almut Mecke

Since Specialization

Citations

This map shows the geographic impact of Almut Mecke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Almut Mecke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Almut Mecke more than expected).

Fields of papers citing papers by Almut Mecke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Almut Mecke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Almut Mecke. The network helps show where Almut Mecke may publish in the future.

Co-authorship network of co-authors of Almut Mecke

This figure shows the co-authorship network connecting the top 25 collaborators of Almut Mecke. A scholar is included among the top collaborators of Almut Mecke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Almut Mecke. Almut Mecke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Matasar, Matthew J., et al.. (2024). Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States. Blood. 144(Supplement 1). 3648–3648.

Galsky, Matthew D., José Ángel Arranz, Enrique Grande, et al.. (2021). Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. Cancer Research. 81(13_Supplement). CT042–CT042. 8 indexed citations

Davis, Ian D., Matthew D. Galsky, Xavier García del Muro, et al.. (2021). Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130. Cancer Research. 81(13_Supplement). CT040–CT040. 5 indexed citations

Galsky, Matt D., Aristotelis Bamias, Jóse Ángel Arranz Arija, et al.. (2021). Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.. Journal of Clinical Oncology. 39(6_suppl). 434–434. 10 indexed citations

Morrissey, Kari M., Mathilde Marchand, Hina Patel, et al.. (2019). Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology. 84(6). 1257–1267. 62 indexed citations

Luhn, Patricia, Jane Yuet Ching Hui, Jingbo Yi, et al.. (2019). Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. Journal of Comparative Effectiveness Research. 8(14). 1173–1185. 9 indexed citations

Grande, Enrique, Matt D. Galsky, Maria De Santis, et al.. (2019). IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 30. v888–v889. 31 indexed citations

Galsky, Matt D., Enrique Grande, Ian D. Davis, et al.. (2018). IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 36(15_suppl). TPS4589–TPS4589. 18 indexed citations

Hui, Jane Yuet Ching, et al.. (2018). Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice. Annals of Oncology. 29. viii101–viii101. 2 indexed citations

10.

Fizazi, Karim, Silke Gillessen, Charles G. Drake, et al.. (2017). A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). TPS5090–TPS5090. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact